An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel

Lauren C. Harshman MD, Kathryn P. Gray PhD, Laura Polacek, Mary-Ellen Taplin MD, Atish Choudhury MD, Mark Pomerantz MD, Joaquim Bellmunt MD, Channing Yu MD PhD, Zijie Sun PhD, Sandy Srinivas MD, Philip W. Kantoff MD, Christopher J. Sweeney MBBS

1 Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
2 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3 Department of Urology, Stanford University School of Medicine, Palo Alto, CA
4 Department of Oncology, Stanford Cancer Center, Stanford University School of Medicine, Palo Alto, CA
5 Memorial Sloan Kettering Cancer Center, New York

Background: Inhibition of the androgen receptor (AR) may de-repress c-Met, which may play a role in progression to CRPC, metastasis, and therapeutic resistance. Preclinical work has shown that crizotinib, a multi-kinase inhibitor including c-Met receptor tyrosine kinase, ROS1, and anaplastic lymphoma kinase, can inhibit prostate cancer growth in cell lines and mouse models. To capitalize on the established efficacy of enzalutamide in CRPC while counteracting induction of c-Met due to AR inhibition, we investigated the combination of crizotinib plus enzalutamide.

Methods: A phase 1, standard 3+3 dose-escalation design was executed to assess the safety, tolerability, and pharmacokinetics of the combination in patients with mCRPC. The primary objective was to identify the maximally tolerated dose (MTD). A fixed standard dose of enzalutamide 160 mg daily plus escalating doses of crizotinib (250 mg daily, 200 mg bid, 250 mg bid) were administered in Cohorts 1, 2 and 3, respectively. The dose limiting toxicity (DLT) period was the first cycle (28 days).

Results: The dose escalation phase has completed. 16 men with ECOG PS 0 or 1 were enrolled in this phase. Median age was 69.5 years. Median baseline PSA was 18.9 ng/dL (range: 0.91-822.2). Visceral disease was present in 31%. The majority (56%) had prior docetaxel. The MTD was full doses of both agents. Cohorts 2 and 3 each had 1 of 6 patients with a grade 3 DLT of transaminitis. The most common, all grade treatment-related AEs were: elevated ALT (10), fatigue (9), elevated AST (9), nausea (6), hypertension (5), diarrhea (4), vomiting (4), constipation (3), edema (2), and dysgeusia (2). There were 6 grade 3/4, at least possibly treatment-related adverse events (AEs): increased ALT (2), hypertension (1), cardiac (3 AEs in same event: cardiac arrest, Vfib, prolonged QTc). Most AEs were grade 1 or 2. All transaminase elevations occurred in the same 4 patients. The dose expansion phase has completed accrual at the MTD. 5 patients remain on study.

Conclusions: Full doses of crizotinib and enzalutamide can be combined in mCRPC. The potential for hepatotoxicity exists with both agents but dose limiting toxicity is low. (NCT number: 02207504)

Funding Acknowledgement
Research funding and drug: Astellas/Medivation
Drug support: Pfizer
This work was also supported by the Dana-Farber Prostate Cancer SPORE P50CA090381; Dept of Defense (DOD - W81XWH-14-1-0515). Lauren C. Harshman was also partially funded by a 2013 Prostate Cancer Foundation Young Investigator Award.